ACIU (AC Immune) Current Accrued Expense: $8.83 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ACIU AC Immune SA ACIU
49 GF Score
Price $2.65
GF Value $3.39
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is AC Immune Current Accrued Expense?

AC Immune ACIU -1.87% 49 Current Accrued Expense is $8.83 Mil as of Jun. 2026. GuruFocus rates ACIU with a GF Score™ of 49/100 and a GF Value™ of $3.39 (Modestly Undervalued). The stock has 5 warning signs investors should review.

AC Immune's Current Accrued Expense for the quarter that ended in Jun. 2026 was $8.83 Mil.

AC Immune's quarterly Current Accrued Expense increased from Dec. 2025 ($4.47 Mil) to Mar. 2026 ($8.05 Mil) and increased from Mar. 2026 ($8.05 Mil) to Jun. 2026 ($8.83 Mil).

AC Immune's annual Current Accrued Expense increased from Dec. 2023 ($7.65 Mil) to Dec. 2024 ($8.74 Mil) but then declined from Dec. 2024 ($8.74 Mil) to Dec. 2025 ($4.47 Mil).

AC Immune Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for AC Immune's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AC Immune Current Accrued Expense Chart

AC Immune Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.60 7.05 7.65 8.74 4.47

AC Immune Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.42 15.07 4.47 8.05 8.83
ACIU
49GF Score
AC Immune SA ACIU
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AC Immune Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $8.83 Mil mean?
AC Immune (ACIU) has a Current Accrued Expense of $8.83 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on AC Immune and its competitors.
Is AC Immune's Current Accrued Expense too high?
AC Immune's current Current Accrued Expense is $8.83 Mil. Overall, AC Immune has a GF Score™ of 49/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AC Immune's Current Accrued Expense compare to SION and SRZN?
AC Immune's Current Accrued Expense of $8.83 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on AC Immune and its competitors. AC Immune's current Current Accrued Expense is $8.83 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AC Immune stock overvalued right now?
Based on GuruFocus' analysis, AC Immune (ACIU) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.39, compared to a current price of $2.65 — trading 21.8% below its estimated fair value. The current Current Accrued Expense is $8.83 Mil. AC Immune's overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For AC Immune (ACIU), the current Current Accrued Expense is $8.83 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AC Immune (ACIU) Overvalued in 2026?

Based on GuruFocus' analysis, AC Immune stock appears to be undervalued. The current stock price of $2.65 is trading 21.8% below its estimated GF Value™ of $3.39. GuruFocus considers AC Immune to be Modestly Undervalued.

Key valuation signals for ACIU:

  • Current Accrued Expense: $8.83 Mil
  • GF Value™: $3.39 vs. price of $2.65 (21.8% below fair value)
  • GF Score™: 49/100 with 5 warning signs

No single metric tells the full story. See the ACIU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AC Immune Business Description

Other Exchanges IMR:Germany
Address EPFL Innovation Park, Building B, Lausanne, CHE, 1015
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
49GF Score

Get the complete analysis for ACIU

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.65
Price
$3.39
GF Value